

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano #32,004

Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Email: zelano@mwzb.com

AJZ:kmo

Filed: 19 February 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 2-4, 9-10, 14-15, 18-19, 21, 23, 26, 32, 34, 37, 39, 45, 47, 49, 51, 52 and 54 have been cancelled and therefore no marked up version is necessary. Claims 11, 13, 16-17, 20, 29, 31, 35, 38, 43, 46, 48 and 53 have been amended as follows:

11. (Amended) A transgenic organism according to ~~any of claims 1 through 10~~, wherein the prothrombin or prothrombin-related polypeptide produced in the organism when isolated and purified has a specific activity is 75% to 125% of that of purified human prothrombin.
13. (Amended) A transgenic organism according to ~~any of claims 1 through 10~~, wherein the prothrombin or prothrombin related polypeptide comprises a region having an amino acid sequence 80% to 100% identical to that of a mammalian thrombin.
16. (Amended) A transgenic organism according to claim 153, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.
17. (Amended) A transgenic organism according to ~~any of claims 1 through 10~~, where in the prothrombin or prothrombin related polypeptide comprises a region having an amino acid sequence 80% to 100% identical to that of a mammalian prothrombin.
20. (Amended) A transgenic organism according to claim 197, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.
29. (Amended) A prothrombin or prothrombin-related polypeptide isolated from a transgenic organism according to claim 28 that differs in its post-translational modification from naturally occurring prothrombin polypeptides.

31. (Amended) A prothrombin or prothrombin-related polypeptide according to ~~any of~~ claims 28 through 30 having a specific activity is 75% to 125% of that of purified human prothrombin.

35. (Amended) A prothrombin or prothrombin-related polypeptide according to claim 34~~3~~, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.

38. (Amended) A prothrombin or prothrombin-related polypeptide according to claim 37~~6~~, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.

43. (Amended) A composition according to claim 43~~0~~, wherein the prothrombin or prothrombin-related polypeptide has a specific activity 75% to 125% of that of purified human prothrombin.

46. (Amended) A composition according to claim 45~~4~~, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.

48. (Amended) A composition according to claim 47~~6~~, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.

53. (Amended) A method for treating a wound in a patient comprising a step of administering to said patient a composition according to ~~any of~~ claims 40 through 49~~5~~.